Ganciclovir for Cytomegalovirus after Heart Transplantation

Thomas C. Bailey; Elbert P. Trulock; Gregory A. Storch; William G. Powderly; Drew J. Winston; Andreas Laske; Augusto Gallino; Thierry Carrel; Marko I. Turina; Thomas C. Merigan; Dale Renlund; William Buhles; Edward Stinson

doi:10.1056/NEJM199209173271215

Ganciclovir for Cytomegalovirus after Heart Transplantation

Thomas C. Bailey, Elbert P. Trulock, Gregory A. Storch, William G. Powderly, Drew J. Winston, Andreas Laske, Augusto Gallino, Thierry Carrel, Marko I. Turina, Thomas C. Merigan, Dale Renlund, William Buhles, Edward Stinson

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Abstract

To the Editor: Although the study by Merigan et al. (April 30 issue)¹ demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit is unclear. The definition of CMV syndrome, for example, may have included cases of very mild illness. Furthermore, the patients at highest risk for serious disease (i.e., CMV-seronegative recipients of organs from CMV-seropositive donors) received no benefit from the described course of prophylaxis. We found no benefit from an early, brief course of ganciclovir in…

Original language	English
Pages (from-to)	891-893
Number of pages	3
Journal	New England Journal of Medicine
Volume	327
Issue number	12
DOIs	https://doi.org/10.1056/NEJM199209173271215
State	Published - Sep 17 1992

Access to Document

10.1056/NEJM199209173271215

Cite this

@article{f5219d6f9ff14eae8f47208e2c9307e4,

title = "Ganciclovir for Cytomegalovirus after Heart Transplantation",

abstract = "To the Editor: Although the study by Merigan et al. (April 30 issue)1 demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit is unclear. The definition of CMV syndrome, for example, may have included cases of very mild illness. Furthermore, the patients at highest risk for serious disease (i.e., CMV-seronegative recipients of organs from CMV-seropositive donors) received no benefit from the described course of prophylaxis. We found no benefit from an early, brief course of ganciclovir in…",

author = "Bailey, {Thomas C.} and Trulock, {Elbert P.} and Storch, {Gregory A.} and Powderly, {William G.} and Winston, {Drew J.} and Andreas Laske and Augusto Gallino and Thierry Carrel and Turina, {Marko I.} and Merigan, {Thomas C.} and Dale Renlund and William Buhles and Edward Stinson",

year = "1992",

month = sep,

day = "17",

doi = "10.1056/NEJM199209173271215",

language = "English",

volume = "327",

pages = "891--893",

journal = "New England Journal of Medicine",

issn = "0028-4793",

number = "12",

}

TY - JOUR

T1 - Ganciclovir for Cytomegalovirus after Heart Transplantation

AU - Bailey, Thomas C.

AU - Trulock, Elbert P.

AU - Storch, Gregory A.

AU - Powderly, William G.

AU - Winston, Drew J.

AU - Laske, Andreas

AU - Gallino, Augusto

AU - Carrel, Thierry

AU - Turina, Marko I.

AU - Merigan, Thomas C.

AU - Renlund, Dale

AU - Buhles, William

AU - Stinson, Edward

PY - 1992/9/17

Y1 - 1992/9/17

N2 - To the Editor: Although the study by Merigan et al. (April 30 issue)1 demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit is unclear. The definition of CMV syndrome, for example, may have included cases of very mild illness. Furthermore, the patients at highest risk for serious disease (i.e., CMV-seronegative recipients of organs from CMV-seropositive donors) received no benefit from the described course of prophylaxis. We found no benefit from an early, brief course of ganciclovir in…

AB - To the Editor: Although the study by Merigan et al. (April 30 issue)1 demonstrated that the use of ganciclovir as prophylaxis for cytomegalovirus (CMV) infection in heart-transplant recipients was associated with fewer cases of CMV disease than was placebo, the clinical importance of this benefit is unclear. The definition of CMV syndrome, for example, may have included cases of very mild illness. Furthermore, the patients at highest risk for serious disease (i.e., CMV-seronegative recipients of organs from CMV-seropositive donors) received no benefit from the described course of prophylaxis. We found no benefit from an early, brief course of ganciclovir in…

UR - http://www.scopus.com/inward/record.url?scp=0026779917&partnerID=8YFLogxK

U2 - 10.1056/NEJM199209173271215

DO - 10.1056/NEJM199209173271215

M3 - Letter

C2 - 1324431

AN - SCOPUS:0026779917

SN - 0028-4793

VL - 327

SP - 891

EP - 893

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 12

ER -

Ganciclovir for Cytomegalovirus after Heart Transplantation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this